| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $491K | — | -82.5% |
| SG&A Expense | $1.7M | — | -5.3% |
| Operating Income | -$2.2M | — | +52.8% |
| Net Income | -$2.5M | — | +43.9% |
| EPS (Basic) | -$0.23 | — | +28.1% |
| EPS (Diluted) | -$0.23 | — | +28.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $1.5M | -82.4% | -61.5% |
| Current Assets | $2.2M | -76.6% | -56.0% |
| Current Liabilities | $933K | -84.9% | -64.3% |
| Stockholders' Equity | $1.2M | -60.4% | -55.4% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$7.0M | — | -38.9% |
| Financing Cash Flow | $3.2M | — | +0.0% |